Abstract
Since 2005, every annual meeting of the Japanese Gastroenterological Association has included a core symposium for functional gastrointestinal disorders. At the 6th annual meeting, the core symposium was ‘Pathophysiology and New Treatment’. At the 7th annual meeting, the core symposium was ‘Pathophysiology and Motility’. This review summarizes the papers presented at these meetings. At the 6th meeting, we recognized that Japanese researchers successfully produced and developed many agents that are safe and effective for the treatment of functional gastrointestinal disorders, such as 5-hydroxytryptamine receptor-associated compounds, lubiprostone, Japanese herbal medicine, and other drugs. Data were validated from a clinical as well as an experimental viewpoint. Findings included the effects of sumatriptan and nizatidine, acylated or des-acylated ghrelin, T-cell-activating anti-CD3 antibody, and transient receptor potential vanilloid-1. At the 7th meeting, not only functional dyspepsia and irritable bowel syndrome (IBS), but also non-erosive esophageal reflux disease (NERD) and chronic intestinal pseudo-obstruction were actively discussed from a motility viewpoint, including papers about sham feeding and gastric motility, genetic polymorphism and motility, the role of transient receptor potential A1 on gastric accommodation, esophageal motility and NERD, diagnosis and treatment of chronic intestinal pseudo-obstruction, immunological basis of motility in IBS, developing non-invasive colonic function test, and fecal distribution in IBS patients.
References
1.
Nakada K, Hongo M, Harasawa S, Mine T, Sasaki I, Matsueda K, Kusano M, Hanyuu N, Shibata C: How the subgroups in functional dyspepsia affect the quality of life and therapeutic approaches. Experience from Japanese Mosapride Mega-Study (JMMS). Gastroenterology 2009;136(suppl 1):A183.
2.
Tomita T, Okugawa T, Toyoshima F, Yamasaki T, Sakurai J, Tanaka J, Morita T, Kim Y, Oshima T, Hori K, Watari J, Matsumoto T, Kashiwagi T, Miwa H: 5-HT4 receptor agonist, a mosapride citrate, facilitates both gastric accommodation and emptying in healthy volunteers. The 17th United European Gastroenterological Week, London, UK, 2009, 11.25.
3.
Futagami S, Shimpuku M, Kawagoe T, Kusunoki M, Ueki N, Miyake K, Iwakiri K, Sakamoto C: Nizatidine administration improves clinical symptoms and gastric emptying of the patients with functional dyspepsia accompanying with impaired gastric emptying. Gastroenterology 2011;140(suppl 1):S230.
4.
Shindo T, Futagami S, Hiratsuka T, Horie A, Hamamoto T, Ueki N, Kusunoki M, Miyake K, Gudis K, Tsukui T, Iwakiri K, Sakamoto C: Comparison of gastric emptying and plasma ghrelin levels in patients with functional dyspepsia and non-erosive reflux disease. Digestion 2009;79:65–72.
[PubMed]
5.
Tominaga K, Higuchi K, Ochi M, Kadouchi K, Kawamura E, Tanigawa T, Shiba M, Watanabe T, Fujiwara Y, Oshitani N, Shiomi S, Arakawa T: Concurrent assessment of reservoir and emptying of the stomach for dyspepsia patients. Hepatogastroenterology 2008;55:744–749.
[PubMed]
6.
Tominaga K, Tsumoto C, Ataka S, Machida H, Okazaki H, Yamagami H, Tanigawa T, Watanabe K, Watanabe T, Fujiwara Y, Shiomi S, Watanabe Y, Arakawa T: Overlapped heartburn/regurgitation amplifies abdominal pain and indigestion via common central serotonin neurotransmission disorders in patients with functional dyspepsia. Gastroenterology 2010;138(suppl 1):S370.
7.
Mizukami T, Suzuki H, Hibi T: Classification and treatment of irritable bowel syndrome based on colonoscopy abnormal bowel motility type and abnormal bowel morphology type. Gastroenterology 2010;138 (suppl 1):S233.
8.
Onodera S, Chiba T, Sugai T, Habano W: A genetic association between β3-aderenoceptor and cholinergic receptor muscarinic-3 polymorphisms in irritable bowel syndrome. Hepatogastroenterology 2011;58:110–111.
9.
Akiho H, Nakamura K: Daikenchuto ameliorates muscle hypercontractility in a murine T-cell-mediated persistent gut motor dysfunction model. Digestion 2011;83:173–179.
[PubMed]
10.
Matsumoto K, Kurosawa E, Terui H, Hosoya T, Tashima K, Murayama T, Priestley JV, Horie S: Localization of TRPV1 and contractile effect of capsaicin in mouse large intestine: high abundance and sensitivity in rectum and distal colon. Am J Physiol Gastrointest Liver Physiol 2009;297:G348–G360.
[PubMed]
11.
Matsumoto K, Hosoya T, Tashima K, Namiki T, Murayama T, Horie S: Distribution of transient receptor potential vanilloid-1 channel-expressing nerve fibers in mouse rectal and colonic enteric nervous system: relationship to peptidergic and nitrergic neurons. Neuroscience 2011;172:518–534.
[PubMed]
12.
Manabe N, Nakamura K, Hara M, et al: Impaired gastric response to modified sham feeding in patients with postprandial distress syndrome. Neurogastroenterol Motil 2011;23:215–219, e112.
[PubMed]
13.
Kondo T, Oshima T, Obata K, et al: Role of transient receptor potential A1 in gastric nociception. Digestion 2010;82:150–155.
[PubMed]
14.
Iwakiri K, Sano H, Tanaka Y, et al: Characteristics of symptomatic reflux episodes in patients with non-erosive reflux disease who have a positive symptom index on proton pump inhibitor therapy. Digestion 2010;82:156–161.
[PubMed]
15.
Akiho H, Ihara E, Nakamura K: Low-grade inflammation plays a pivotal role in gastrointestinal dysfunction in irritable bowel syndrome. World J Gastrointest Pathophysiol 2010;1:97–105.
16.
Kusunoki H, Kamada T, Sato M, et al: Ultrasonographic assessment of sigmoid colon in patients with irritable bowel syndrome (in Japanese). Nihon Rinsho 2006;64:1461–1466.
[PubMed]
17.
Miyata K, Ito H, Fukudo S: Involvement of the 5-HT3 receptor in CRH-induced defecation in rats. Am J Physiol 1998;274:G827–G831.
[PubMed]
18.
Fukudo S, Hongo M, Kaneko H, Ueno R: Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: a randomized, placebo-controlled and dose-finding study. Neurogastroenterol Motil 2011;23:544-e205.
[PubMed]
19.
Miwa H, Nagahara A, Tominaga K, Yokoyama T, Sawada Y, Inoue K, Ashida K, Fukuchi T, Hojo M, Yamashita H, Tomita T, Hori K, Oshima T: Efficacy of the 5-HT1A agonist tandospirone citrate in improving symptoms of patients with functional dyspepsia: a randomized controlled trial. Am J Gastroenterol 2009;104:2779–2787.
[PubMed]
20.
Matsueda K, Hongo M, Tack J, Aoki H, Saito Y, Kato H: Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia – 100 mg tid is an optimal dosage. Neurogastroenterol Motil 2010;22:618–e173.
[PubMed]
21.
Kanazawa M, Watanabe S, Tana C, Komuro H, Aoki M, Fukudo S: Effect of 5-HT4 receptor agonist mosapride citrate on rectosigmoid sensorimotor function in patients with irritable bowel syndrome. Neurogastroenterol Motil 2011;23:754-e332.
[PubMed]
© 2012 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2012
You do not currently have access to this content.
